Preliminary Flu Vaccine Effectiveness (VE) Data for 2022-2023

Español | Other Languages
Print
Related Pages

CDC Reference (severe flu outcomes): Olson, Lewis, Tenforde 2023 [4.5 MB, 25 pages]

Marshfield, WI Reference (medically attended flu illness): McLean, et al., 2023

New Vaccine Surveillance Network (NVSN)

NVSN

Table 1: Vaccine effectiveness against laboratory confirmed influenza A in inpatient and emergency department (ED) settings, September 13, 2022-January 25, 2023
Vaccine Effectiveness
Influenza positive Influenza negative1 Adjusted2
N vaccinated /Total (%) N vaccinated /Total (%) VE % 95% CI
Influenza A All 6 mos – 17 years 123/640 19 750/2256 33 49 (36 to 60)
Inpatient 19/131 15 288/913 32 68 (46 to 81)
ED 104/507 21 461/1330 35 42 (25 to 56)
A/H3N2 98/478 21 750/2256 33 45 (29 to 58)
A/H1N1pdm09 23/139 17 750/2256 33 56 (28 to 72)

1 Persons testing negative for both influenza and SARS-CoV-2 using molecular assays.

2 Multivariable logistic regression models adjusted for site, age, and calendar time.

Investigating Respiratory Viruses in the Acutely Ill (IVY) Network

IVY

Table 2: Vaccine effectiveness against laboratory confirmed influenza A in inpatient settings, October 1, 2022-January 31, 2023
Vaccine Effectiveness
Influenza positive Influenza negative1 Adjusted2
N vaccinated /Total (%) N vaccinated /Total (%) VE % 95% CI
≥18 years 219/701 31 921/2130 43 43 (30 to 54)
18-64 years 84/378 22 365/1021 36 51 (33 to 64)
≥65 years 135/323 42 556/1109 50 35 (13 to 52)
Immunicompromised3 45/122 37 238/474 50 44 (10 to 66)

1 Persons testing negative for influenza and SARS-CoV-2 using molecular assays.

2 Multivariable logistic regression models adjusted for Census region, age, sex, race/ethnicity, and month.

3 Includes active solid-organ cancer, active hematologic cancer, solid-organ transplant, bone marrow/stem cell transplant, HIV infection, congenital immunodeficiency syndrome, use of an immunosuppressive medication within the last 30 days, splenectomy, graft-versus-host disease (currently or in the past), or any other condition that causes moderate or severe immunosuppression.

VISION Vaccine Effectiveness Network

VISION

Table 3: Vaccine effectiveness against laboratory confirmed influenza A in emergency department/urgent care settings, October 15, 2022-January 24, 2023
Vaccine Effectiveness
Influenza positive Influenza negative Adjusted1
N vaccinated /Total (%) N vaccinated /Total (%) VE % 95% CI
All adults ≥ 18 years 3278/14011 (23) 15752/43196 (36) 44 (41 to 47)
18-64 years 1600/10590 (15) 6695/27545 (24) 46 (42 to 49)
≥ 65 years 1678/3421 (49) 9057/15651 (58) 39 (34 to 43)
Immunicompromised2 64/179 (36) 553/1363 (41) 30 (-2 to 52)

1 Adjusted for patient age, study site, and calendar time.

2 Defined as at least one discharge diagnosis for solid malignancy, hematologic malignancy, rheumatologic or inflammatory disorder, other intrinsic immune condition or immunodeficiency, or organ or stem cell transplant.

Table 4: Vaccine effectiveness against laboratory confirmed influenza A in hospital settings, October 15, 2022-January 21, 2023
Vaccine Effectiveness
Influenza positive Influenza negative Adjusted1
N vaccinated /Total (%) N vaccinated /Total (%) VE % 95% CI
All adults ≥ 18 years 671/1760 (38) 4561/9377 (49) 39 (31 to 45)
18-64 years 146/623 (23) 802/2739 (29) 29 (12 to 43)
≥ 65 years 525/1137 (46) 3759/6638 (57) 42 (34 to 49)
Immunicompromised2 130/297 (44) 1172/2316 (51) 31 (10 to 48)

1 Adjusted for patient age, study site, and calendar time.

2 Defined as at least one discharge diagnosis for solid malignancy, hematologic malignancy, rheumatologic or inflammatory disorder, other intrinsic immune condition or immunodeficiency, or organ or stem cell transplant.

Related Publications

McLean HQ, Petrie JG, Hanson KE, et al. Interim Estimates of 2022–23 Seasonal Influenza Vaccine Effectiveness — Wisconsin, October 2022–February 2023. MMWR Morb Mortal Wkly Rep 2023;72:201–205. DOI: http://dx.doi.org/10.15585/mmwr.mm7208a1.